Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 10 of 27
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
NCT05338502
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
NCT03670810
A Drug Interaction Study of LY3154207 in Healthy Participants
NCT03942029
A Study of LY3502970 in Healthy Participants
NCT03929744
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
NCT03954834
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
NCT03936959
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
NCT03933943
A Study of the Effects of LY3372689 on the Brain in Healthy Participants
NCT03944031
A Study of Different Injectable Formulations of LY3375880 in Healthy Participants
NCT03913260
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
NCT05630274
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
NCT03740919
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03882970
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
NCT03890003
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
NCT03742973
A Study of Injections of LY3074828 in Healthy Participants
NCT03886948
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
NCT03849612
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges
NCT03848767
A Study of LY900014 in a Medtronic Pump
NCT03760640
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
NCT03830281
A Study of Selpercatinib (LY3527723) in Healthy Participants
NCT05338515
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT03831191
A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes
NCT03758430
A Safety Study of LY3372689 Given By Mouth to Healthy Participants
NCT03819270
A Study of LY3405105 in Participants With Advanced Cancer
NCT03770494
A Study of Ixekizumab in Healthy Participants
NCT03848416
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
NCT05469113
Study of Ixekizumab in Healthy Participants
NCT03848403
An Interaction Study of LY3200882 in Healthy Participants
NCT03792139
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
NCT05469100
A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
NCT05436912
A Study of LY3463251 in Healthy Participants
NCT03764774
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
NCT03750643
A Study of LY3415244 in Participants With Advanced Solid Tumors
NCT03752177
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
NCT03730662
A Study of LY3090106 in Japanese and Caucasian Healthy Participants
NCT03736772
A Study Comparing User Experience of Different Delivery Devices for Glucagon
NCT03765502
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
NCT03736785
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
NCT03743285
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03573323
A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT03720548
A Study of LY3361237 in Healthy Participants
NCT03695198
A Study of Mirikizumab in Participants With Plaque Psoriasis
NCT03718884
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03524092
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
NCT03724981
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
NCT03570749
A Study of Two Formulations of LY3074828 in Healthy Participants
NCT03662100
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
NCT03556202
Study of LY3154207 in Healthy Participants
NCT03616795
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
NCT03616964
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.